But thank heavens a stage three trial is sequentially next after a mid-stage phase 2 trial, which Cellceutix currently has no less than 4 delivering topline results in 2017.
I like to think of the B-UP and B-OM trials this way, yes they are small but no other pharma large or small except for cellceutix has anything even close to target these horrible unmet medical needs. P is a fairly large blinded with a good chance to outshine Otezla. K a small test run targeting only ovarian chemo resistant cell lines, if and when this pans out a broader trial is sure to come. Why put the focus on Kevetrin at this point when UP and OM are dare I say a sure thing.
The term "mid stage" has nothing to do with how a trial is powered or whether it is placebo controlled (though the stages do inform the decision), it has to do with efficacy and dose optimization as well as refining characterization. Safety only enters as an element of optimization through dose escalation.